Be The Match BioTherapies
VC Fund
Be The Match BioTherapies is a VC fund focused on Therapeutics and Biotechnology. Be The Match BioTherapies® is built on the foundation established by our parent company.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Be The Match BioTherapies invests in
Stages Be The Match BioTherapies invests in
Countries Be The Match BioTherapies invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amy Ronneberg
|
|||
Chris McClain
|
|||
Investment Focus
Industry
- Therapeutics 2 (40%)
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Genetics 1 (20%)
- Health Care 1 (20%)
Stage
- Series B 2 (40%)
- Series A 1 (20%)
- Series C 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Amy Ronneberg
President
|
President | Total investments: 0 | Find email | |
|
Chris McClain
SVP, Sales , Business Development, Cell & Gene Therapy
|
SVP, Sales , Business Development, Cell & Gene Therapy | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tmunity Therapeutics
|
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $75M / Series B / Oct 31, 2019 | |
|
Tmunity Therapeutics
|
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $35M / Series A / Apr 19, 2018 | |
Magenta Therapeutics
|
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastatinghematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects. | $52M / Series C / Apr 09, 2018 | |
|
Tmunity Therapeutics
|
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $100M / Series A / Jan 23, 2018 | |
|
Magenta Therapeutics
|
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastatinghematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects. | $50M / Series B / May 02, 2017 |
Co-Investors
Access Industries
2 deals together
Casdin Capital
2 deals together
Gilead Sciences
2 deals together
Lilly Asia Ventures
2 deals together
Parker Institute for Cancer Immunotherapy
2 deals together
Penn Medicine Co-Investment Program
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Be The Match BioTherapies invest in?
Be The Match BioTherapies invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Be The Match BioTherapies?
Public channels for Be The Match BioTherapies include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Be The Match BioTherapies?
The team at Be The Match BioTherapies includes Amy Ronneberg (President) and Chris McClain (SVP, Sales , Business Development, Cell & Gene Therapy). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
